Table 1 Characteristics of mCRPC patients included in this study
P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | P11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Age | 66 | 68 | 47 | 61 | 73 | 63 | 82 | 83 | 79 | 67 | 88 |
Activity (GBq) | 3.7 | 3.7 | 3.7 | 3.7 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.1 | 6.1 |
Cycle | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 1 | 1 |
Metastases (VIS = visceral, LYM = lymph, OSS = osseous) | OSS | Mainly VIS (liver), OSS, LYM | Mainly OSS, LYM | Mainly OSS, LYM | Mainly OSS, LYM | OSS, LYM | Mainly OSS, LYM, VIS | Mainly OSS, LYM, VIS | Mainly OSS, LYM | Mainly OSS, LYM | OSS |
Initial TNM classification and Gleason score | pT4, N1, R1, G3, Gleason 8 | pT3b, pN1, R0, G3, Gleason 9 | pT3a, pN1, pR1, Gleason 9 | pT3b, pN1, R1, Gleason 9 | pT3b, pN1 | T3a, N1 | pT4, pN1, R1, G3, Gleason 9 | pT4, pN1, R1, G3, Gleason 9 | n.a. | pT3, pN0, R1, Gleason 7 | n.a. |
PSA (ng/ml) prior to RLT | 1201 | 368 | 408 | 5436 | 2311 | 0.86 | 65.7 | 65.6 | 418 | 20.6 | 52.1 |
Pre-therapies (1, yes/0, no) | |||||||||||
▪ Surgery | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
▪ Radiotherapy | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 |
▪ Anti-hormonal therapy (including 2nd line anti-hormonal therapy with bicalutamide, enzalutamide, abiraterone acetate) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
▪ Ra-223 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
▪ Chemotherapy (docetaxel, cabazitaxel) | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
Blood baseline | |||||||||||
▪ Leukocytes (G/l) | 7.2 | 4.9 | 6 | 5.6 | 5.2 | 4.54 | 5.41 | 4.85 | 5.31 | 2.73 | 7.84 |
▪ Lymphocytes (G/l0 | 0.57 | 0.96 | 1.71 | 0.49 | 0.56 | 1.14 | 0.95 | 0.48 | 0.94 | 0.28 | 2.06 |
▪ Hemoglobin (g/dl) | 14.1 | 12.3 | 12.8 | 9.6 | 10.9 | 13.3 | 10.5 | 8.4 | 10.5 | 8.3 | 12.1 |
▪ Thrombocytes (G/l) | 195 | 307 | 323 | 291 | 235 | 227 | 450 | 305 | 223 | 89 | 281 |
▪ Erythrocytes (T/l) | 4.79 | 4.31 | 4.36 | 4.08 | 3.86 | 4.11 | 3.96 | 3.25 | 3.55 | 3.2 | 3.64 |